TY  - GEN

T1  - 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis

PY  - 2022/09/01

AU  - Weidinger S

AU  - Bieber T

AU  - Cork M

ED  - 

Y2  - 2024/12/22

ER  -